ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM).

Trial Profile

ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms ATREUS
  • Most Recent Events

    • 03 Aug 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2017.
    • 02 Aug 2017 Planned End Date changed from 1 Oct 2016 to 1 Nov 2017.
    • 06 Jun 2017 Results (n=71) assessing the activity and safety of Trabectedin in patients with epithelioid malignant pleural mesothelioma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top